


**Supplementary Table 1.** Frequencies of spondyloarthritis features in each subgroup.

	ASAS axSpA criteria  N = 2423 (%)	ASAS axSpA and CASPAR criteria  N = 354 (%)	CASPAR criteria  N = 218 (%)	CASPAR and ASAS criteria  N = 322 (%)	ASAS peripheral SpA criteria  N = 236 (%)	Whole group ASAS axSpA criteria  N = 2777 (%)	Whole group ASAS peripheral SpA criteria  N = 558 (%)	Whole group CASPAR criteria  N = 894 (%)
<b>HLA-B27</b>	1684 (69.5)	174 (49.2)	15 (6.9)	38 (11.8)	144 (61.0)	1858 (66.9)	182 (32.6)	227 (25.4)
<b>X-ray sacroiliitis</b>	1907 (78.7)	272 (76.8)	37 (17.0)	53 (16.5)	121 (51.3)	2179 (78.5)	174 (31.2)	362 (40.5)
<b>MRI sacroiliitis</b>	1000 (41.3)	133 (37.6)	20 (9.2)	29 (9.0)	72 (30.5)	1133 (40.8)	101 (18.1)	182 (20.4)
<b>Abnormal CRP</b>	1377 (56.8)	220 (62.1)	79 (36.2)	134 (41.6)	137 (58.1)	1597 (57.5)	271 (48.6)	433 (48.4)
<b>Uveitis</b>	540 (22.3)	72 (20.3)	16 (7.3)	24 (7.5)	48 (20.3)	612 (22.0)	72 (12.9)	112 (12.5)
<b>Arthritis</b>	902 (37.2)	254 (71.8)	199 (91.3)	317 (98.4)	187 (79.2)	1156 (41.6)	504 (90.3)	770 (86.1)
<b>Enthesitis</b>	780 (32.2)	186 (52.5)	110 (50.5)	130 (40.4)	148 (62.7)	966 (34.8)	278 (49.8)	426 (47.7)
<b>Dactylitis</b>	127 (5.2)	132 (37.3)	99 (45.4)	170 (52.8)	41 (17.4)	259 (9.3)	211 (37.8)	401 (44.9)
<b>Family history of SpA</b>	628 (25.9)	67 (18.9)	6 (2.8)	20 (6.2)	60 (25.4)	695 (25.0)	80 (14.3)	93 (10.4)
<b>Psoriasis</b>	5 (0.2)	216 (61.0)	163 (74.8)	246 (76.4)	3 (1.3)	211 (8.0)	249 (44.6)	625 (69.9)
<b>IBD</b>	118 (4.9)	33 (9.3)	8 (3.7)	9 (2.8)	13 (5.5)	151 (5.4)	22 (3.9)	50 (5.6)

axSpA: axial Spondyloarthritis; CRP: C-reactive protein; IBD: Inflammatory Bowel Disease; IBP: Inflammatory Back Pain; MRI: Magnetic resonance imaging; SpA: Spondyloarthritis.


**Supplementary Figure 1:** Number of swollen joints among patients with peripheral arthritis at the time of the study.



**Supplementary Table 2:** Distribution of peripheral manifestations across continents.

	Europe N = 1705 (%)	Africa N = 337 (%)	Asia N = 1094 (%)	Middle East N = 254 (%)	South America N = 352 (%)	North America N = 242 (%)
<b>Any peripheral manifestation</b>	1166 (68.4)	263 (78.0)	536 (49.0)	135 (53.1)	295 (83.8)	167 (69.0)
<b>Peripheral arthritis</b>	923 (54.1)	226 (67.1)	436 (39.9)	65 (25.6)	249 (70.7)	152 (62.8)
<b>Peripheral enthesitis</b>	657 (38.5)	181 (53.7)	294 (26.9)	105 (41.3)	210 (59.7)	59 (24.4)
<b>Dactylitis</b>	288 (16.9)	557 (15.3)	110 (10.1)	13 (5.1)	82 (23.3)	64 (26.4)

**Supplementary Figure 2.** Time of occurrence of each peripheral manifestation regarding axial symptoms onset among patients with axial involvement.



**Supplementary Table 3:** Associated factors with current or ever peripheral dactylitis. Multivariate logistic regression.

<b>Characteristic</b>	<b>Dactylitis</b>	<b>No dactylitis</b>	<b>OR (95%CI)<sup>1</sup></b>	<b>p-value</b>
	<b>n = 618 (%)</b>	<b>n = 3366 (%)</b>		
<b>Age ≥ 43 years</b>	392 (63.4)	1558 (46.3)	1.33 (1.08-1.63)	0.008
<b>Gender (female)</b>	277 (44.8)	1117 (33.2)		
<b>Socioeducational level (university)</b>	295 (47.7)	1388 (41.2)	1.49 (1.22-1.84)	<0.001
<b>South America</b>	82 (13.3)	270 (8.0)		
<b>Obese (BMI ≥ 30)</b>	156 (25.2)	607 (18.0)		
<b>HLA-B27 negative</b>	399 (64.6)	1368 (40.6)	1.48 (1.19-1.84)	<0.001
<b>Absence chronic IBP</b>	232 (37.5)	527 (15.7)	1.81 (1.45-2.27)	<0.001
<b>Peripheral arthritis</b>	590 (95.5)	1789 (53.1)	6.95 (5.16-9.36)	<0.001
<b>Peripheral enthesitis</b>	378 (61.2)	1128 (33.5)	2.51 (2.05-3.06)	<0.001
<b>Uveitis</b>	114 (18.4)	655 (19.5)		
<b>Psoriasis</b>	244 (39.5)	390 (11.6)	2.08 (1.64-2.64)	<0.001
<b>Family history of Psoriasis</b>	171 (27.7)	373 (11.1)	1.60 (1.25-2.03)	<0.001
<b>IBD</b>	29 (4.7)	179 (5.3)		
<b>Never smoking</b>	383 (62.0)	1755 (52.1)	1.44 (1.18-1.76)	<0.001
<b>Never alcohol intake</b>	304 (49.2)	1615 (48.0)		

Hosmer-Lemeshow test:  $\chi^2$  square = 17.401, p=0.026

<sup>1</sup>OR (95%CI) for statistically significative variables which remain in the final model. Percentages indicate number of patients with the covariate from the total number of patients in each disease clinical form. BMI: Body Mass Index; IBD: Inflammatory Bowel Disease.


**Supplementary Table 4:** Impact of each peripheral manifestation on the treatment.

	Total = 3984	PERIPHERAL ARTHRITIS			PERIPHERAL ENTHESITIS			DACTYLITIS		
		Yes = 2051 n (%)	No = 328 n (%)	p- value <sup>1</sup>	Yes = 1506 n (%)	No = 2478 n (%)	p- value <sup>1</sup>	Yes = 618 n (%)	No = 3366 n (%)	p- value <sup>1</sup>
<b>NSAIDs</b>										
% of patients since the onset of SpA symptoms	3548(89.0)	1858 (90.6)	1690(87.4)	<b>0.001</b>	1402 (93.1)	2146 (86.6)	<b>&lt;0.001</b>	568 (91.9)	2980 (88.5)	<b>0.013</b>
<b>DMARDs INTAKE (PAST OR PRESENT)</b>										
csDMARDs	2371(59.5)	1581(77.1)	790(40.9)	<b>&lt;0.001</b>	1062(70.5)	1309(52.8)	<b>&lt;0.001</b>	492 (79.6)	1879 (55.8)	<b>&lt;0.001</b>
bDMARDs	1742(43.7)	987(48.1)	755(39.1)	<b>&lt;0.001</b>	750(49.8)	992(40.0)	<b>&lt;0.001</b>	330 (53.4)	1412 (41.9)	<b>&lt;0.001</b>
<b>CORTICOSTEROIDS</b>										
% of patients using corticosteroids	1523 (38.2)	1048 (51.1)	475 (24.6)	<b>&lt;0.001</b>	738 (49.0)	785 (31.7)	<b>&lt;0.001</b>	330 (53.4)	1193 (35.4)	<b>&lt;0.001</b>
Current prednisone intake (mg), mean(SD)	1.01 (4.18)	1.54 (5.15)	0.45 (0.06)	<b>&lt;0.001</b>	1.26 (5.12)	0.86 (3.48)	<b>0.008</b>	1.70 (5.55)	0.88 (3.86)	<b>0.001</b>
Estimated total intake (mg), mean(SD)	1741(6901)	2651 (8442)	773 (4544)	<b>&lt;0.001</b>	2185(7466.)	1488(6523)	<b>0.004</b>	2477 (7529)	1606 (6771)	<b>0.008</b>


<sup>1</sup>Chi-square and T-test for qualitative and quantitative variables, respectively.

Percentages indicate number of patients with the covariate from the total number of patients in each column.

**Supplementary Figure 3:** Impact of peripheral arthritis on PROs depending on its presence at the time of the study.



**Supplementary Figure 4:** Impact of peripheral enthesitis on PROs depending on its presence at the time of the study.



**Supplementary Figure 5:** Impact of dactylitis on PROs depending on its presence at the time of the study.

